SMGs in mouse AML identify SMGs in human AML that are potential AML1-ETO cooperating partners. (A) The patients that harbor nonsynonymous mutations in genes that are significantly mutated in human AML (FDR ≤ 30%). (B) For the genes significantly mutated in human AML, the types of mutations present in mouse AML samples are depicted. Those genes that are significantly mutated in a given mouse AML group (FDR ≤ 10%) are highlighted in blue under the given group. (C) TET2 mutations identified in t(8;21)⁺ AML patients. (D) PTPN11 mutations identified in AML patients.